| Date Filed | Type | Description |
| 10/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/06/2023 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 15.3% stake in Abeona Therapeutics Inc. |
| 07/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT Abeona Therapeutics Inc. Warrant Shares : ______________ Issue Date: July ___ , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, [●] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Abeona Therapeutics Inc., a Delaware corporation , up to _____ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meani...",
"Tel: 212 728 8000 Fax: 212 728 8111",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of July 3, 2023, between Abeona Therapeutics Inc., a Delaware corporation , and the purchasers identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended and the rules and regulations of the Securities and Exchange Commission thereunder, the Company desires to issue and sell to the several Purchasers, and the several Purchasers desire to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration t...",
"Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules" |
|
| 07/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/19/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/17/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G
| Nantahala Capital Management, LLC reports a 7.9% stake in ABEONA THERAPEUTICS INC |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 6.4% stake in ABEONA THERAPEUTICS INC. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 5.1% stake in Abeona Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2023 |
SC 13G/A
| HIRSCHMAN ORIN reports a 3.8% stake in Abeona Therapeutics Inc. |
| 12/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/16/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/14/2022 |
SC 13G
| EcoR1 Capital, LLC reports a 10% stake in Abeona Therapeutics Inc. |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
SC 13G
| Point72 Asset Management, L.P. reports a 10% stake in Abeona Therapeutics Inc. |
| 11/04/2022 |
SC 13G
| HIRSCHMAN ORIN reports a 6.1% stake in Abeona Therapeutics Inc. |
| 11/03/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
|